Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Central Nervous System Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


2 drugs have received FDA approval for Central Nervous System Cancer . Methotrexate Sodium and Uridine Triacetate
198 drugs have a clinical trial registered for Central Nervous System Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 646 clinical trials for Central Nervous System Cancer,
437 of which have one or more drug interventions,
209 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 531 Cell Line Models for Central Nervous System Cancer.

Source: COSMIC
(see details)

Chemistry


There are 4219 Compounds which have been tested in Central Nervous System Cancer , 3038 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Central Nervous System Cancer:
Central Nervous System Neoplasms
Neoplasms, Nerve Tissue
Nerve Sheath Neoplasms
Nervous System Neoplasms
Optic Nerve Neoplasms
Peripheral Nervous System Neoplasms

The following terms have been mapped from cancer.gov to Central Nervous System Cancer:
Acute lymphoblastic leukemia that has spread to the central nervous system, or to prevent it from spreading there
Cardiac (heart) or central nervous system toxicity or other serious side effects within 4 days of ending treatment with fluorouracil or capecitabine